Volume 29, Issue 3
DOI: 10.24205/03276716.2020.716
Up-regulation of Long Noncoding RNA BSN-AS2 is Correlated with Tumor Progression and Poor Prognosis in Patients with Bladder Cancer
Abstract
OBJECTIVE: The purpose of this study was to explore the associations between long noncoding RNA BSN-AS2 (BSN-AS2) expression and clinical significance of bladder cancer (BC) patients.
PATIENTS AND METHODS: The expressions of BSN-AS2 were determined in 168 BC tissues and matched non-tumor samples using qRT-PCR. The receiver operating characteristic (ROC) curve was performed to estimate the diagnostic significance of BSN-AS2 in BC patients. The association between BSN-AS2 expression and clinicopathological parameters was analyzed. Kaplan-Meier curves and multivariate assays were applied to examine the impact of clinical factors on clinical survivals.
RESULTS: The expression of BSN-AS2 in BC tissues was distinctly higher than that of their matched non-tumor specimens (p < 0.001). High BSN-AS2 levels were observed to be robust in differentiating BC specimens from non-tumor bladder tissues (AUC= 0.7698, p < 0.001). BSN-AS2 expression was significantly associated with T stage (p = 0.016) and grade (p = 0.007). Survival data indicated that high expression of BSN-AS2 had a decreased overall survival (p = 0.0017) and disease-free survival (p < 0.0001). Multivariate analysis revealed that increased BSN-AS2 expression was an independent risk factor for BC patients.
CONCLUSIONS: Our findings, for the first time, demonstrated that BSN-AS2 expression in BC could be a useful prognostic and diagnostic marker.
Keywords
LncRNA BSN-AS2, Bladder cancer, Diagnosis, Prognosis.